✦ LIBER ✦
Effects of C5 complement inhibitor pexelizumab on outcome in high-risk coronary artery bypass grafting: Combined results from the PRIMO-CABG I and II trials
✍ Scribed by Peter K. Smith; Stanton K. Shernan; John C. Chen; Michel Carrier; Edward D. Verrier; Peter X. Adams; Thomas G. Todaro; Lawrence H. Muhlbaier; Jerrold H. Levy
- Book ID
- 113764202
- Publisher
- CTSNet
- Year
- 2011
- Tongue
- English
- Weight
- 297 KB
- Volume
- 142
- Category
- Article
- ISSN
- 1097-685X
No coin nor oath required. For personal study only.